Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Contributed by: Business Wire

Logo

Tags

Infectious Diseases

Biotechnology

Pharmaceutical

Health

More Like This

Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults1

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

Business Wire associated0

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Polish Ministry of Health Approves Reimbursement of POTELIGEO® (mogamulizumab) for Adults Living With Mycosis Fungoides or Sézary Syndrome

PR Newswire associated0

SUANFARMA announces a collaboration with Reyoung Pharmaceutical to expand the existing portfolio of anti-infective and antibacterial products

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow